Investigational Drug Information for ATN-161
✉ Email this page to a colleague
What is the drug development status for ATN-161?
ATN-161 is an investigational drug.
There have been 27 clinical trials for ATN-161.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Acute Kidney Injury, HIV Infections, and Renal Insufficiency. The leading clinical trial sponsors are University of North Carolina, Chapel Hill, Attenuon, and National Institute of Mental Health (NIMH).
There are one hundred and twenty-two US patents protecting this investigational drug and one international patent.
Summary for ATN-161
| US Patents | 122 |
| International Patents | 1,181 |
| US Patent Applications | 331 |
| WIPO Patent Applications | 211 |
| Japanese Patent Applications | 62 |
| Clinical Trial Progress | Phase 2 (2019-04-01) |
| Vendors | 31 |
Recent Clinical Trials for ATN-161
| Title | Sponsor | Phase |
|---|---|---|
| RM1 Project 1 - tAN Naloxone | Medical University of South Carolina | Early Phase 1 |
| Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant | Centre National de la Recherche Scientifique, France | Phase 3 |
| Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant | Institut National de la Santé Et de la Recherche Médicale, France | Phase 3 |
Clinical Trial Summary for ATN-161
Top disease conditions for ATN-161
Top clinical trial sponsors for ATN-161
US Patents for ATN-161
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ATN-161 | ⤷ Try a Trial | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | Alkermes, Inc. (Waltham, MA) | ⤷ Try a Trial |
| ATN-161 | ⤷ Try a Trial | Fluorinated integrin antagonists | SciFluor Life Sciences, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| ATN-161 | ⤷ Try a Trial | Nonanoic and decanoic acid derivatives and uses thereof | SciFluor Life Sciences, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| ATN-161 | ⤷ Try a Trial | Methods and systems for treating or preventing cancer | Transdermal Biotechnology, Inc. (Meriden, CT) | ⤷ Try a Trial |
| ATN-161 | ⤷ Try a Trial | XTEN conjugate compositions and methods of making same | Amunix Operating Inc. (Mountain View, CA) | ⤷ Try a Trial |
| ATN-161 | ⤷ Try a Trial | Fusion polypeptides comprising mucin-domain polypeptide linkers | Alkermes, Inc. (Waltham, MA) | ⤷ Try a Trial |
| ATN-161 | ⤷ Try a Trial | Small molecule inhibitors of EGFR and PI3K | The Regents of the University of Michigan (Ann Arbor, MI) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ATN-161
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ATN-161 | Australia | AU2013271541 | 2032-06-08 | ⤷ Try a Trial |
| ATN-161 | Australia | AU2013271542 | 2032-06-08 | ⤷ Try a Trial |
| ATN-161 | Australia | AU2013271545 | 2032-06-08 | ⤷ Try a Trial |
| ATN-161 | Australia | AU2015268652 | 2032-06-08 | ⤷ Try a Trial |
| ATN-161 | Australia | AU2018200597 | 2032-06-08 | ⤷ Try a Trial |
| ATN-161 | Canada | CA2869674 | 2032-06-08 | ⤷ Try a Trial |
| ATN-161 | Canada | CA2869786 | 2032-06-08 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
